LawrenceT.FriedhoffMD

Physician

Dr. Friedhoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Lawrence Friedhoff, MD, based in New York, NY, specializes in Internal Medicine with residency training from Rutgers Health/Robert Wood Johnson Medical School and Icahn School of Medicine at Mount Sinai/Beth Israel. He has a noted experience in drug development and has authored several publications, including a guide on the FDA's drug approval process and led studies of Alzheimer's disease which led to the FDA approval of donepezil HCl, the first practical treatment for Alzheimer’s disease. He has led the development and FDA approvals of multiple other drugs. His approved drugs are used by many millions pot patients. His work has been published in reputable journals, including one publication that was the 11th most widely cited biotech publication in the year it was published. He has started several companies that grew to multibillion-dollar organizations with hundreds or thousands of employees.

Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1981 - 1982
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1977 - 1978
New York University School of MedicineClass of 1977

Study of SkQ1 as Treatment for Dry-eye Syndrome Start of enrollment: 2018 Dec 06
Completed
Phase 3

PubMed

3 citations
A call for a global ‘bigger’ data approach to Alzheimer disease
Eric D. Perakslis, Henry Riordan, Lawrence Friedhoff, Azmi Nabulsi, Emilio Merlo Pich
Nature Reviews. Drug Discovery. 2019-05-01
9 citations
Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys.
Simon Authier, Michael V. Accardi, Dominique Paquette, Mylene Pouliot, Joseph C. Arezzo
Journal of Pharmacological and Toxicological Methods. 2016-09-01
12 citations
Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.
Paul Glue, Gavin Cape, Donna Tunnicliff, Michelle Marie Lockhart, Fred Lam
Journal of Clinical Pharmacology. 2016-08-01

Books/Book Chapters

New Drugs: An Insider's Guide to the FDA's New Drug Approval Process
Lawrence FriedhoffPSPG Publishing, New York

INmune Bio Doses First Alzheimer’s Disease Patient in XPro1595 StudyDecember 2nd, 2019
INmune Bio Inc. To Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference WebinarNovember 26th, 2019
Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer’s Disease at CTAD 2016December 5th, 2016
Join now to see all

Head of Research and Development, Roivant Sciences, Inc.One of four original employees. Designer of the unique management structure which has proved to provide more efficient/effective FDA approvals.2014 - 2020